Agonists, Antagonists, and Modulators of P2X7 Receptors

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2022 Jul 1

PMID 35776318

Authors

Christa E Muller

Vigneshwaran Namasivayam

Affiliations

Soon will be listed here.

Abstract

The P2X7 receptor has been proposed as a novel drug target for different types of diseases associated with inflammation, including brain diseases, peripheral inflammation, and cancers. Structurally diverse P2X7 receptor antagonists, mainly negative allosteric modulators (NAMs), have been developed in recent years, and several P2X7 receptor antagonists are currently evaluated in clinical trials. The P2X7 receptor requires high micro- to even millimolar ATP concentrations to be activated. Selective agonists for the P2X7 receptor are not available. Positive allosteric modulators (PAMs) have been described, but PAMs with high potency and selectivity are still lacking. This chapter discusses medicinal chemistry approaches toward the development of P2X7 receptor modulators and presents a selection of recommended tool compounds for studying P2X7 receptors in humans and rodents.

Citing Articles

Establishment and behavioural characterization of a novel constitutive P2X7 receptor knockout mouse line.

von Mucke-Heim I, Oldekamp J, Metzger M, Klaffgen S, Tang H, Walser S Purinergic Signal. 2025; .

PMID: 40024982 DOI: 10.1007/s11302-025-10074-x.

Screening herbal and natural product libraries to aid discovery of novel allosteric modulators of human P2X7.

Bidula S, Piyasirananda W, Bielecka H, Bibic L, Beekman A, Stokes L Purinergic Signal. 2024; .

PMID: 39436616 DOI: 10.1007/s11302-024-10055-6.

Implication of lncRNA MSTRG.81401 in Hippocampal Pyroptosis Induced by P2X7 Receptor in Type 2 Diabetic Rats with Neuropathic Pain Combined with Depression.

Zhan T, Tang S, Du J, Liu J, Yu B, Yang Y Int J Mol Sci. 2024; 25(2).

PMID: 38256257 PMC: 10816120. DOI: 10.3390/ijms25021186.

The P2X7 Receptor in Oncogenesis and Metastatic Dissemination: New Insights on Vesicular Release and Adenosinergic Crosstalk.

Adinolfi E, De Marchi E, Grignolo M, Szymczak B, Pegoraro A Int J Mol Sci. 2023; 24(18).

PMID: 37762206 PMC: 10531279. DOI: 10.3390/ijms241813906.

Tetracyclic 1,4-Naphthoquinone Thioglucoside Conjugate U-556 Blocks the Purinergic P2X7 Receptor in Macrophages and Exhibits Anti-Inflammatory Activity In Vivo.

Kozlovskiy S, Pislyagin E, Menchinskaya E, Chingizova E, Kaluzhskiy L, Ivanov A Int J Mol Sci. 2023; 24(15).

PMID: 37569745 PMC: 10418395. DOI: 10.3390/ijms241512370.

References

Illes P, Muller C, Jacobson K, Grutter T, Nicke A, Fountain S . Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. Br J Pharmacol. 2020; 178(3):489-514. PMC: 8199792. DOI: 10.1111/bph.15299. View

Jacobson K, Delicado E, Gachet C, Kennedy C, von Kugelgen I, Li B . Update of P2Y receptor pharmacology: IUPHAR Review 27. Br J Pharmacol. 2020; 177(11):2413-2433. PMC: 7205808. DOI: 10.1111/bph.15005. View

Zimmermann H . Ectonucleoside triphosphate diphosphohydrolases and ecto-5'-nucleotidase in purinergic signaling: how the field developed and where we are now. Purinergic Signal. 2020; 17(1):117-125. PMC: 7954995. DOI: 10.1007/s11302-020-09755-6. View

Adinolfi E, Giuliani A, De Marchi E, Pegoraro A, Orioli E, Di Virgilio F . The P2X7 receptor: A main player in inflammation. Biochem Pharmacol. 2017; 151:234-244. DOI: 10.1016/j.bcp.2017.12.021. View

Oliveira-Giacomelli A, Petiz L, Andrejew R, Turrini N, Silva J, Sack U . Role of P2X7 Receptors in Immune Responses During Neurodegeneration. Front Cell Neurosci. 2021; 15:662935. PMC: 8187565. DOI: 10.3389/fncel.2021.662935. View

Burnstock G, Knight G . The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal. 2017; 14(1):1-18. PMC: 5842154. DOI: 10.1007/s11302-017-9593-0. View

Amores-Iniesta J, Barbera-Cremades M, Martinez C, Pons J, Revilla-Nuin B, Martinez-Alarcon L . Extracellular ATP Activates the NLRP3 Inflammasome and Is an Early Danger Signal of Skin Allograft Rejection. Cell Rep. 2017; 21(12):3414-3426. PMC: 5746605. DOI: 10.1016/j.celrep.2017.11.079. View

Sarti A, Vultaggio-Poma V, Di Virgilio F . P2X7: a receptor with a split personality that raises new hopes for anti-cancer therapy. Purinergic Signal. 2021; 17(2):175-178. PMC: 8155152. DOI: 10.1007/s11302-021-09783-w. View

Di Virgilio F, Vultaggio-Poma V, Sarti A . P2X receptors in cancer growth and progression. Biochem Pharmacol. 2020; 187:114350. DOI: 10.1016/j.bcp.2020.114350. View

10.

Lord B, Aluisio L, Shoblock J, Neff R, Varlinskaya E, Ceusters M . Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. J Pharmacol Exp Ther. 2014; 351(3):628-41. DOI: 10.1124/jpet.114.218487. View

11.

Di Virgilio F, Schmalzing G, Markwardt F . The Elusive P2X7 Macropore. Trends Cell Biol. 2018; 28(5):392-404. DOI: 10.1016/j.tcb.2018.01.005. View

12.

Kwak S, Shin S, Lee J, Shim J, Kim M, Lee S . Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells. Eur J Med Chem. 2018; 151:462-481. DOI: 10.1016/j.ejmech.2018.03.023. View

13.

Homerin G, Jawhara S, Dezitter X, Baudelet D, Dufrenoy P, Rigo B . Pyroglutamide-Based P2X7 Receptor Antagonists Targeting Inflammatory Bowel Disease. J Med Chem. 2019; 63(5):2074-2094. DOI: 10.1021/acs.jmedchem.9b00584. View

14.

Rech J, Bhattacharya A, Letavic M, Savall B . The evolution of P2X7 antagonists with a focus on CNS indications. Bioorg Med Chem Lett. 2016; 26(16):3838-45. DOI: 10.1016/j.bmcl.2016.06.048. View

15.

Muller C . Medicinal chemistry of P2X receptors: allosteric modulators. Curr Med Chem. 2014; 22(7):929-41. DOI: 10.2174/0929867322666141210155610. View

16.

Coddou C, Stojilkovic S, Huidobro-Toro J . Allosteric modulation of ATP-gated P2X receptor channels. Rev Neurosci. 2011; 22(3):335-54. PMC: 3647606. DOI: 10.1515/RNS.2011.014. View

17.

Michel A, Fonfria E . Agonist potency at P2X7 receptors is modulated by structurally diverse lipids. Br J Pharmacol. 2007; 152(4):523-37. PMC: 2050815. DOI: 10.1038/sj.bjp.0707417. View

18.

Alloisio S, Aiello R, Ferroni S, Nobile M . Potentiation of native and recombinant P2X7-mediated calcium signaling by arachidonic acid in cultured cortical astrocytes and human embryonic kidney 293 cells. Mol Pharmacol. 2006; 69(6):1975-83. DOI: 10.1124/mol.105.020164. View

19.

Piyasirananda W, Beekman A, Ganesan A, Bidula S, Stokes L . Insights into the Structure-Activity Relationship of Glycosides as Positive Allosteric Modulators Acting on P2X7 Receptors. Mol Pharmacol. 2020; 99(2):163-174. PMC: 7816042. DOI: 10.1124/molpharm.120.000129. View

20.

Asatryan L, Ostrovskaya O, Lieu D, Davies D . Ethanol differentially modulates P2X4 and P2X7 receptor activity and function in BV2 microglial cells. Neuropharmacology. 2017; 128:11-21. PMC: 6492934. DOI: 10.1016/j.neuropharm.2017.09.030. View